Literature DB >> 18327252

Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila.

Shuang Chang1, Steven M Bray, Zigang Li, Daniela C Zarnescu, Chuan He, Peng Jin, Stephen T Warren.   

Abstract

Fragile X syndrome is caused by the functional loss of the fragile X mental retardation 1 (FMR1) gene. Deletion of the FMR1 ortholog in Drosophila melanogaster (Fmr1) recapitulates many phenotypes associated with fragile X syndrome. We have discovered that Fmr1 mutant Drosophila die during development when reared on food containing increased levels of glutamate, which is consistent with the theory that FMR1 loss results in excess glutamate signaling. Using this lethal phenotype, we screened a chemical library of 2,000 compounds and identified nine molecules that rescued the lethality, including three that implicate the GABAergic inhibitory pathway. Indeed, GABA treatment rescued several known Fmr1 mutant phenotypes in flies, including mushroom bodies defects, excess Futsch translation and abnormal male courtship behavior. These data are consistent with GABAergic inhibition of the enhanced excitatory pathway in fragile X syndrome. In addition, our screen reveals that the muscarinic cholinergic receptors may have a role in fragile X syndrome in parallel to the GABAergic pathway. These results point to potential therapeutic approaches for treating fragile X syndrome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18327252     DOI: 10.1038/nchembio.78

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   15.040


  129 in total

1.  Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.

Authors:  Laura K K Pacey; Sujeenthar Tharmalingam; David R Hampson
Journal:  J Pharmacol Exp Ther       Date:  2011-06-02       Impact factor: 4.030

Review 2.  Fragile X syndrome: the GABAergic system and circuit dysfunction.

Authors:  Scott M Paluszkiewicz; Brandon S Martin; Molly M Huntsman
Journal:  Dev Neurosci       Date:  2011-09-21       Impact factor: 2.984

3.  In vivo analysis of compound activity and mechanism of action using epistasis in Drosophila.

Authors:  Erdem Bangi; Dan Garza; Marc Hild
Journal:  J Chem Biol       Date:  2010-12-22

Review 4.  Drosophila and Galleria insect model hosts: new tools for the study of fungal virulence, pharmacology and immunology.

Authors:  Michail S Lionakis
Journal:  Virulence       Date:  2011 Nov-Dec       Impact factor: 5.882

5.  Linking model systems to cancer therapeutics: the case of Mastermind.

Authors:  Barry Yedvobnick; Ken Moberg
Journal:  Dis Model Mech       Date:  2010-07-27       Impact factor: 5.758

Review 6.  Potential therapeutic interventions for fragile X syndrome.

Authors:  Josien Levenga; Femke M S de Vrij; Ben A Oostra; Rob Willemsen
Journal:  Trends Mol Med       Date:  2010-09-21       Impact factor: 11.951

Review 7.  Pharmacological lifespan extension of invertebrates.

Authors:  Mark Lucanic; Gordon J Lithgow; Silvestre Alavez
Journal:  Ageing Res Rev       Date:  2012-07-06       Impact factor: 10.895

8.  Soy-based diet exacerbates seizures in mouse models of neurological disease.

Authors:  Cara J Westmark; Pamela R Westmark; James S Malter
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 9.  Drug screening in Drosophila; why, when, and when not?

Authors:  Tin Tin Su
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2019-05-05       Impact factor: 5.814

Review 10.  Lithium: a promising treatment for fragile X syndrome.

Authors:  Zhonghua Liu; Carolyn Beebe Smith
Journal:  ACS Chem Neurosci       Date:  2014-05-15       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.